A Sum Score to Define Therapy-Refractory Myasthenia Gravis: A German Consensus
Background and purpose: In 2017, eculizumab has been approved for treatment-refractory generalised myasthenia gravis (TRgMG). The German Myasthenia Foundation has published a consensus statement on the use of eculizumab, with a recent update. However, a treatment-refractory state is still ill-define...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-02-01
|
| Series: | Journal of Central Nervous System Disease |
| Online Access: | https://doi.org/10.1177/1179573521989151 |